

Supplementary Material

Comparative Safety of Pulsed Field Ablation and Cryoballoon Ablation Technologies for Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation: An Indirect Treatment Comparison

Authors:

Sonia Maccioni^{*1}, Reecha Sharma², Donghyun D. Lee³, Anja Haltner⁴, Rahul Khanna⁵, Johan Vijgen⁶

Author Affiliations:

¹Johnson & Johnson Medical Devices, Franchise Health Economics and Market Access, Irvine, CA 92618, USA

²Johnson & Johnson Medical Devices, Clinical Research, Irvine, CA 92618, USA

³EVERSANA™, Burlington, Ontario, Canada

⁴EVERSANA™, Chicago, Illinois, USA



⁵Medical Device Epidemiology and Real-World Data Sciences, Johnson & Johnson, New Brunswick, NJ, USA

⁶Cardiology Department, Jessa Hospitals, Hasselt, Belgium (J.V.).

***Corresponding Author: Sonia Maccioni**


E-mail: smaccion@its.jnj.com

Supplemental Figure S1: Meta-Analysis of PFA and CBA trials for the composite of major adverse events



Abbreviations: CBA, cryoballoon ablation; CI, confidence interval; PFA, pulsed field ablation

Supplemental Figure S2: Meta-Analysis of PFA and CBA trials for composite of prespecified adverse events



Abbreviations: CBA, cryoballoon ablation; CI, confidence interval; PFA, pulsed field ablation

Supplemental Table S1: Summary of sensitivity analyses of composite major adverse events between PFA and CBA trials

Outcome	Indirect Comparison		Single-arm meta-analyses	
	PFA vs CBA Risk Difference % (95% CI)	PFA vs CBA Risk Ratio (95% CI)	PFA Events % (95% CI)	CBA Events % (95% CI)
<i>Sensitivity analyses on composite of major safety events:</i>				
Removing FreezeAF	-3.2 (-4.6, -1.7)	0.20 (0.09, 0.59)	0.4 (0.0, 1.3)	4.2 (1.7, 6.7)
Removing Fire and Ice	-6.1 (-8.1, -4.1)	0.12 (0.05, 0.34)	0.4 (0.0, 1.3)	6.7 (4.1, 9.3)
Removing SUPIR	-4.3 (-5.8, -2.8)	0.16 (0.07, 0.45)	0.4 (0.0, 1.3)	5.7 (2.4, 9.0)
Removing plusONE	-4.0 (-5.6, -2.5)	0.17 (0.07, 0.48)	0.4 (0.0, 1.3)	5.3 (1.9, 8.7)

Abbreviations: CBA, cryoballoon ablation; CI, confidence interval; PFA, pulsed field ablation

Note: Statistically significant results are bolded. Composite of major adverse events include cardiac tamponade or perforation, major vascular access complication or bleeding, myocardial infarction (MI), pericardial effusion, pericarditis, phrenic nerve paralysis, stroke, cerebrovascular accident (CVA), thromboembolism, transient ischemic attack (TIA), atrio-esophageal fistula, device- or procedure-related death, and pulmonary vein (PV) stenosis..